HC Wainwright Issues Pessimistic Forecast for Telix Pharmaceuticals (NASDAQ:TLX) Stock Price

Telix Pharmaceuticals (NASDAQ:TLX) had its price objective dropped by research analysts at HC Wainwright from $23.00 to $20.00 in a note issued to investors on Wednesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 114.59% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Finally, William Blair reiterated an “outperform” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

Telix Pharmaceuticals Stock Down 3.8%

Shares of TLX stock opened at $9.32 on Wednesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. Telix Pharmaceuticals has a twelve month low of $8.93 and a twelve month high of $30.36. The business has a fifty day simple moving average of $12.67 and a 200 day simple moving average of $15.51.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TLX. Private Advisor Group LLC acquired a new stake in Telix Pharmaceuticals during the first quarter worth approximately $170,000. ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals during the first quarter worth approximately $451,000. Blair William & Co. IL acquired a new stake in Telix Pharmaceuticals during the second quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $297,000. Finally, Pier Capital LLC acquired a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $3,037,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.